# Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

> **NCT06022003** · PHASE2 · RECRUITING · sponsor: **French Innovative Leukemia Organisation** · enrollment: 33 (estimated)

## Conditions studied

- AML, Adult
- Refractory AML
- Relapsed Adult AML
- FLT3-TKD Mutation
- FLT3-ITD

## Interventions

- **DRUG:** AzaCITIDine Oral Tablet
- **DRUG:** Xospata

## Key facts

- **NCT ID:** NCT06022003
- **Lead sponsor:** French Innovative Leukemia Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-13
- **Primary completion:** 2026-10
- **Final completion:** 2027-10
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06022003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06022003, "Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06022003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*